neoag
Neoantigen × AI
Daily research signal
№28Brief2026-07-02

NOA16 IDH1 Astrocytoma Vaccine Shows Long-Term Survival

The NOA16 trial reports long-term survival data for an IDH1-mutant astrocytoma vaccine, highlighting the clinical potential of targeting clonal driver mutations.PubMed

Concurrently, Ruijin Hospital initiates a Phase 1 study of the personalized vaccine ABO2109 combined with toripalimab in solid tumors.trial

2new stories1 in context
ClinicaltodayNew

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

Ruijin Hospital has launched a Phase 1 study recruiting patients for ABO2109, a personalized cancer vaccine administered with the PD-1 inhibitor toripalimab. The trial evaluates safety, tolerability, immunogenicity, and antitumor activity in solid tumors across dose exploration and expansion stages. This marks an early-stage clinical entry for ABO2109, aiming to generate data supporting its broader development.

clinicaltrials · today · Ruijin Hospital

Also new today01

01
ClinicalyesterdayNew

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

The NOA16 trial provides 8-year follow-up data for an IDH1-R132H peptide vaccine in newly diagnosed astrocytoma, demonstrating sustained immunogenicity and favorable long-term outcomes. Participants with grade IV disease achieved a median overall survival of 106.1 months, significantly outperforming historical controls. Sustained antibody responses to the neoepitope correlated with favorable clinical courses, validating the target for mutant IDH1-driven cancers.

Peptide vaccines
europepmc · yesterday · Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harti

Catching up01

Relevant work from earlier we're still surfacing — not today's news.

Explore the field

Field MapTrialsPrimer